This article provides a blueprint for a collaborative approach to identifying inhibitors of not only Zika virus but any emerging viral pathogen. Developing a collection of, for example, nucleoside and nucleoside analogue drugs that could be quickly screened would be a useful starting point but developing screens and a detailed understanding of the virus, analogous to that accomplished when the coronavirus SARS emerged, makes considerable sense.